Inebilizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Inebilizumab comprises 77 peer-reviewed publications across 15 journals, 3 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Autoimmune Diseases of the Nervous System, Neuromyelitis Optica, Immunoglobulin G4-Related Disease, and Myasthenia Gravis. Most recent publication: Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)., Mod Rheumatol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.
    Titulaer MJ, McCracken L, Gabilondo I, et al. · Lancet Neurol · 2013
    PubMed: PMID 23290630 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
    Streicher K, Sridhar S, Kuziora M, et al. · Arthritis Rheumatol · 2019
    PubMed: PMID 29956883 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody.
    Malviya M, Barman S, Golombeck KS, et al. · Ann Clin Transl Neurol · 2022
    PubMed: PMID 29159189 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  4. Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis.
    Guasp M, Módena Y, Armangue T, et al. · Neurol Neuroimmunol Neuroinflamm · 2021
    PubMed: PMID 31900318 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  5. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.
    Gresa-Arribas N, Titulaer MJ, Torrents A, et al. · Lancet Neurol · 2014
    PubMed: PMID 24360484 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  6. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.
    Dalmau J, Lancaster E, Martinez-Hernandez E, et al. · Lancet Neurol · 2011
    PubMed: PMID 21163445 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  7. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.
    Dalmau J, Gleichman AJ, Hughes EG, et al. · Lancet Neurol · 2009
    PubMed: PMID 18851928 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  8. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
    Cree BAC, Bennett JL, Kim HJ, et al. · Lancet · 2019
    PubMed: PMID 31495497 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02200770Neuromyelitis OpticaTime to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP
Day 1 (Baseline) through Day 197
Inebilizumab/InebilizumabNA Days
Placebo/InebilizumabNA Days
NCT04524273
MINT
Myasthenia GravisChange From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population
Baseline and Week 26
Overall: Inebilizumab 300 mg-4.2 Score on a scale
Overall: Placebo-2.2 Score on a scale
NCT04540497Immunoglobulin G4-Related DiseaseRCP: Time to Disease Flare
Up to Week 52
Inebilizumab 300 mgNA Days
Placebo246.0 Days

Publications by year

2001–2026: 77 publications.

2001
1
2003
1
2005
2
2007
2
2008
1
2009
1
2010
3
2011
4
2012
1
2013
3
2014
2
2015
5
2016
3
2017
4
2018
1
2019
12
2020
5
2021
5
2022
8
2023
2
2024
5
2025
4
2026
2

Publications by indication

Autoimmune Diseases of the Nervous System (39)

  • NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody.
    Ann Clin Transl Neurol · 2022 · PMID 29159189 · NCT04372615
  • Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis.
    Neurol Neuroimmunol Neuroinflamm · 2021 · PMID 31900318 · NCT04372615
  • N-Methyl-D-Aspartate Receptor Antibodies in Autoimmune Encephalopathy Alter Oligodendrocyte Function.
    Ann Neurol · 2020 · PMID 32052483 · NCT04372615
  • Development of the clinical assessment scale in autoimmune encephalitis.
    Ann Neurol · 2020 · PMID 30675918 · NCT04372615
  • Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors.
    Sci Transl Med · 2020 · PMID 31292262 · NCT04372615

Neuromyelitis Optica (8)

  • Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Lancet Neurol · 2024 · PMID 38760098 · NCT02200770
  • Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    J Neurol Neurosurg Psychiatry · 2023 · PMID 37221052 · NCT02200770
  • Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
    Mult Scler Relat Disord · 2022 · PMID 35158461 · NCT02200770
  • Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
    Mult Scler · 2022 · PMID 33538237 · NCT02200770
  • Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
    EBioMedicine · 2022 · PMID 36370634 · NCT02200770
  • Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE).
    Mod Rheumatol · 2026 · PMID 41786624 · NCT04540497
  • Inebilizumab for Treatment of IgG4-Related Disease.
    N Engl J Med · 2025 · PMID 39541094 · NCT04540497
  • Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
    Rheumatol Ther · 2024 · PMID 37792260 · NCT04540497

Myasthenia Gravis (1)

Arthritis, Rheumatoid (1)

  • Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time?
    J Am Soc Nephrol · 2026 · PMID 41979896 · NCT06570798

Publications by journal

Trial-results highlights

For Myasthenia Gravis, the MINT study (NCT04524273) investigated inebilizumab. The primary outcome measured was the change from baseline at Week 26 in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score in the overall study population. In the inebilizumab 300 mg arm, the least squares mean change was -4.2 on a scale. For the placebo arm, the least squares mean change was -2.2 on a scale.

In a study for Immunoglobulin G4-Related Disease (NCT04540497), the primary endpoint was the time to disease flare during the Randomized Controlled Period (RCP), up to Week 52. The placebo arm reported a median time to disease flare of 246.0 Days. The inebilizumab 300 mg arm reported 'NA' Days for this endpoint.

For Neuromyelitis Optica, the NCT02200770 study evaluated the time to an Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack during the RCP, from Day 1 (Baseline) through Day 197. The median time for the inebilizumab/inebilizumab arm was 'NA' Days. Similarly, the median time for the placebo/inebilizumab arm was also 'NA' Days.

All values are sourced from primary registry reporting; individual publications should be consulted for clinical decision-making.

All Inebilizumab publications (77)

2026 (2 papers)

  1. Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE).
    Tanaka Y, Umehara H, Sato H, et al. · Mod Rheumatol · 2026 · Derived
    PubMed: PMID 41786624 · NCT04540497 · Immunoglobulin G4-Related Disease
  2. Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time?
    Karam S, Boudhabhay I, Jhaveri KD, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41979896 · NCT06570798 · Arthritis, Rheumatoid

2025 (4 papers)

  1. Inebilizumab for Treatment of IgG4-Related Disease.
    Stone JH, Khosroshahi A, Zhang W, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39541094 · NCT04540497 · Immunoglobulin G4-Related Disease
  2. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
    Nowak RJ, Benatar M, Ciafaloni E, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40202593 · NCT04524273 (MINT) · Myasthenia Gravis
  3. Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.
    Häußler V, Trebst C, Engels D, et al. · J Neurol Neurosurg Psychiatry · 2025 · Background
    PubMed: PMID 39730197 · NCT07010302 (BEST-NMOSD)
  4. Prevalence of neuromyelitis optica spectrum disorder in the United States.
    Briggs FB, Shaia J · Mult Scler · 2025 · Background
    PubMed: PMID 38279789 · NCT07010302 (BEST-NMOSD)

2024 (5 papers)

  1. Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
    Perugino C, Culver EL, Khosroshahi A, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37792260 · NCT04540497 · Immunoglobulin G4-Related Disease
  2. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC, Kim HJ, Weinshenker BG, et al. · Lancet Neurol · 2024 · Derived
    PubMed: PMID 38760098 · NCT02200770 · Neuromyelitis Optica
  3. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    Kümpfel T, Giglhuber K, Aktas O, et al. · J Neurol · 2024 · Background
    PubMed: PMID 37676297 · NCT07010302 (BEST-NMOSD)
  4. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
    Duchow A, Bellmann-Strobl J, Friede T, et al. · Ann Neurol · 2024 · Background
    PubMed: PMID 38086777 · NCT07010302 (BEST-NMOSD)
  5. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL, Pittock SJ, Aktas O, et al. · Neurol Ther · 2024 · Background
    PubMed: PMID 38722571 · NCT07010302 (BEST-NMOSD)

2023 (2 papers)

  1. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    Aktas O, Hartung HP, Smith MA, et al. · J Neurol Neurosurg Psychiatry · 2023 · Derived
    PubMed: PMID 37221052 · NCT02200770 · Neuromyelitis Optica
  2. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ, Barnett M, Bennett JL, et al. · Ann Neurol · 2023 · Background
    PubMed: PMID 36866852 · NCT07010302 (BEST-NMOSD)

2022 (8 papers)

  1. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody.
    Malviya M, Barman S, Golombeck KS, et al. · Ann Clin Transl Neurol · 2022 · Trial result
    PubMed: PMID 29159189 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
    Flanagan EP, Levy M, Katz E, et al. · Mult Scler Relat Disord · 2022 · Derived
    PubMed: PMID 35158461 · NCT02200770 · Neuromyelitis Optica
  3. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
    Cree BA, Bennett JL, Kim HJ, et al. · Mult Scler · 2022 · Derived
    PubMed: PMID 33538237 · NCT02200770 · Neuromyelitis Optica
  4. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
    Bennett JL, Aktas O, Rees WA, et al. · EBioMedicine · 2022 · Derived
    PubMed: PMID 36370634 · NCT02200770 · Neuromyelitis Optica
  5. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
    Yamamura T, Weinshenker B, Yeaman MR, et al. · Mult Scler Relat Disord · 2022 · Background
    PubMed: PMID 36007339 · NCT07010302 (BEST-NMOSD)
  6. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
    Rensel M, Zabeti A, Mealy MA, et al. · Mult Scler · 2022 · Background
    PubMed: PMID 34595983 · NCT07010302 (BEST-NMOSD)
  7. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.
    Marcinnò A, Marnetto F, Valentino P, et al. · Neurol Neuroimmunol Neuroinflamm · 2022 · Background
    PubMed: PMID 30258855 · NCT07010302 (BEST-NMOSD)
  8. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P, Vasileiou ES, Filippatou AG, et al. · Neurology · 2022 · Background
    PubMed: PMID 36240094 · NCT07010302 (BEST-NMOSD)

2021 (5 papers)

  1. Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis.
    Guasp M, Módena Y, Armangue T, et al. · Neurol Neuroimmunol Neuroinflamm · 2021 · Trial result
    PubMed: PMID 31900318 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
    Marignier R, Bennett JL, Kim HJ, et al. · Neurol Neuroimmunol Neuroinflamm · 2021 · Derived
    PubMed: PMID 33771837 · NCT02200770 · Neuromyelitis Optica
  3. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Aktas O, Smith MA, Rees WA, et al. · Ann Neurol · 2021 · Derived
    PubMed: PMID 33724534 · NCT02200770 · Neuromyelitis Optica
  4. Dynamically borrowing strength from another study through shrinkage estimation.
    Röver C, Friede T · Stat Methods Med Res · 2021 · Background
    PubMed: PMID 30821201 · NCT07010302 (BEST-NMOSD)
  5. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK.
    O'Connell K, Hamilton-Shield A, Woodhall M, et al. · J Neurol Neurosurg Psychiatry · 2021 · Background
    PubMed: PMID 32576617 · NCT07010302 (BEST-NMOSD)

2020 (5 papers)

  1. N-Methyl-D-Aspartate Receptor Antibodies in Autoimmune Encephalopathy Alter Oligodendrocyte Function.
    Matute C, Palma A, Serrano-Regal MP, et al. · Ann Neurol · 2020 · Trial result
    PubMed: PMID 32052483 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Development of the clinical assessment scale in autoimmune encephalitis.
    Lim JA, Lee ST, Moon J, et al. · Ann Neurol · 2020 · Trial result
    PubMed: PMID 30675918 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors.
    Jones BE, Tovar KR, Goehring A, et al. · Sci Transl Med · 2020 · Trial result
    PubMed: PMID 31292262 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  4. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.
    Chen D, Gallagher S, Monson NL, et al. · J Clin Med · 2020 · Trial result
    PubMed: PMID 27886126 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  5. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M, Oeda T, Okada K, et al. · Lancet Neurol · 2020 · Background
    PubMed: PMID 32199095 · NCT07010302 (BEST-NMOSD)

2019 (12 papers)

  1. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
    Warikoo N, Brunwasser SJ, Benz A, et al. · J Neurosci · 2019 · Trial result
    PubMed: PMID 29476014 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
    Streicher K, Sridhar S, Kuziora M, et al. · Arthritis Rheumatol · 2019 · Trial result
    PubMed: PMID 29956883 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications.
    Makuch M, Wilson R, Al-Diwani A, et al. · Ann Neurol · 2019 · Trial result
    PubMed: PMID 29406578 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  4. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor.
    Hara M, Martinez-Hernandez E, Ariño H, et al. · Neurology · 2019 · Trial result
    PubMed: PMID 29549218 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  5. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis.
    Dubey D, Pittock SJ, Kelly CR, et al. · Ann Neurol · 2019 · Trial result
    PubMed: PMID 29293273 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  6. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
    Cree BAC, Bennett JL, Kim HJ, et al. · Lancet · 2019 · Trial result
    PubMed: PMID 31495497 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  7. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.
    Balu R, McCracken L, Lancaster E, et al. · Neurology · 2019 · Trial result
    PubMed: PMID 30578370 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  8. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Agius MA, Klodowska-Duda G, Maciejowski M, et al. · Mult Scler · 2019 · Trial result
    PubMed: PMID 29143550 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  9. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T, Kleiter I, Fujihara K, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31774956 · NCT07010302 (BEST-NMOSD)
  10. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ, Berthele A, Fujihara K, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31050279 · NCT07010302 (BEST-NMOSD)
  11. Mortality in neuromyelitis optica is strongly associated with African ancestry.
    Mealy MA, Kessler RA, Rimler Z, et al. · Neurol Neuroimmunol Neuroinflamm · 2019 · Background
    PubMed: PMID 29892608 · NCT07010302 (BEST-NMOSD)
  12. Racial differences in neuromyelitis optica spectrum disorder.
    Kim SH, Mealy MA, Levy M, et al. · Neurology · 2019 · Background
    PubMed: PMID 30366977 · NCT07010302 (BEST-NMOSD)

2018 (1 paper)

  1. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
    Cree BA, Bennett JL, Sheehan M, et al. · Mult Scler · 2018 · Derived
    PubMed: PMID 26666258 · NCT02200770 · Neuromyelitis Optica

2017 (4 papers)

  1. Features of Human CD3+CD20+ T Cells.
    Schuh E, Berer K, Mulazzani M, et al. · J Immunol · 2017 · Trial result
    PubMed: PMID 27412413 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E, Chatterjee S, Hsu V, et al. · Arthritis Res Ther · 2017 · Trial result
    PubMed: PMID 27267753 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity.
    Planagumà J, Haselmann H, Mannara F, et al. · Ann Neurol · 2017 · Trial result
    PubMed: PMID 27399303 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  4. Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis.
    Kothur K, Wienholt L, Mohammad SS, et al. · PLoS One · 2017 · Trial result
    PubMed: PMID 27575749 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2016 (3 papers)

  1. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
    Nosadini M, Alper G, Riney CJ, et al. · Neurol Neuroimmunol Neuroinflamm · 2016 · Background
    PubMed: PMID 26819962 · NCT07010302 (BEST-NMOSD)
  2. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.
    Kleiter I, Gold R · Neurotherapeutics · 2016 · Background
    PubMed: PMID 26597098 · NCT07010302 (BEST-NMOSD)
  3. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.
    Kleiter I, Gahlen A, Borisow N, et al. · Ann Neurol · 2016 · Background
    PubMed: PMID 26537743 · NCT07010302 (BEST-NMOSD)

2015 (5 papers)

  1. Rationale for B cell targeting in SLE.
    Sanz I · Semin Immunopathol · 2015 · Trial result
    PubMed: PMID 24763533 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.
    Planagumà J, Leypoldt F, Mannara F, et al. · Brain · 2015 · Trial result
    PubMed: PMID 25392198 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.
    Mei HE, Wirries I, Frölich D, et al. · Blood · 2015 · Trial result
    PubMed: PMID 25573986 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  4. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.
    Halliley JL, Tipton CM, Liesveld J, et al. · Immunity · 2015 · Trial result
    PubMed: PMID 26187412 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  5. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
    Wingerchuk DM, Banwell B, Bennett JL, et al. · Neurology · 2015 · Background
    PubMed: PMID 26092914 · NCT07010302 (BEST-NMOSD)

2014 (2 papers)

  1. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.
    Gresa-Arribas N, Titulaer MJ, Torrents A, et al. · Lancet Neurol · 2014 · Trial result
    PubMed: PMID 24360484 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
    Trebst C, Jarius S, Berthele A, et al. · J Neurol · 2014 · Background
    PubMed: PMID 24272588 · NCT07010302 (BEST-NMOSD)

2013 (3 papers)

  1. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.
    Titulaer MJ, McCracken L, Gabilondo I, et al. · Lancet Neurol · 2013 · Trial result
    PubMed: PMID 23290630 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Cerebrospinal fluid CD19(+) B-cell expansion in N-methyl-D-aspartate receptor encephalitis.
    Dale RC, Pillai S, Brilot F, et al. · Dev Med Child Neurol · 2013 · Trial result
    PubMed: PMID 23151040 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH, Huh SY, Lee SJ, et al. · JAMA Neurol · 2013 · Background
    PubMed: PMID 23897062 · NCT07010302 (BEST-NMOSD)

2012 (1 paper)

  1. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
    Kitley J, Leite MI, Nakashima I, et al. · Brain · 2012 · Background
    PubMed: PMID 22577216 · NCT07010302 (BEST-NMOSD)

2011 (4 papers)

  1. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma.
    Tüzün E, Zhou L, Baehring JM, et al. · Acta Neuropathol · 2011 · Trial result
    PubMed: PMID 19680671 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab.
    Mei HE, Frölich D, Giesecke C, et al. · Blood · 2011 · Trial result
    PubMed: PMID 20829370 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. Analysis of relapses in anti-NMDAR encephalitis.
    Gabilondo I, Saiz A, Galán L, et al. · Neurology · 2011 · Trial result
    PubMed: PMID 21865579 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  4. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.
    Dalmau J, Lancaster E, Martinez-Hernandez E, et al. · Lancet Neurol · 2011 · Trial result
    PubMed: PMID 21163445 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2010 (3 papers)

  1. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.
    Hughes EG, Peng X, Gleichman AJ, et al. · J Neurosci · 2010 · Trial result
    PubMed: PMID 20427647 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
    Herbst R, Wang Y, Gallagher S, et al. · J Pharmacol Exp Ther · 2010 · Trial result
    PubMed: PMID 20605905 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  3. EFNS guidelines on diagnosis and management of neuromyelitis optica.
    Sellner J, Boggild M, Clanet M, et al. · Eur J Neurol · 2010 · Background
    PubMed: PMID 20528913 · NCT07010302 (BEST-NMOSD)

2009 (1 paper)

  1. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.
    Dalmau J, Gleichman AJ, Hughes EG, et al. · Lancet Neurol · 2009 · Trial result
    PubMed: PMID 18851928 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2008 (1 paper)

  1. Cytokine-producing B lymphocytes-key regulators of immunity.
    Lund FE · Curr Opin Immunol · 2008 · Trial result
    PubMed: PMID 18417336 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2007 (2 papers)

  1. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
    Muldoon LL, Soussain C, Jahnke K, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17538176 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.
    Dalmau J, Tüzün E, Wu HY, et al. · Ann Neurol · 2007 · Trial result
    PubMed: PMID 17262855 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2005 (2 papers)

  1. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.
    Nasreddine ZS, Phillips NA, Bédirian V, et al. · J Am Geriatr Soc · 2005 · Trial result
    PubMed: PMID 15817019 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System
  2. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease.
    Lund FE, Garvy BA, Randall TD, et al. · Curr Dir Autoimmun · 2005 · Trial result
    PubMed: PMID 15564716 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2003 (1 paper)

  1. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.
    Rubenstein JL, Combs D, Rosenberg J, et al. · Blood · 2003 · Trial result
    PubMed: PMID 12393404 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

2001 (1 paper)

  1. The FAB: a Frontal Assessment Battery at bedside.
    Dubois B, Slachevsky A, Litvan I, et al. · Neurology · 2001 · Trial result
    PubMed: PMID 11113214 · NCT04372615 (ExTINGUISH) · Autoimmune Diseases of the Nervous System

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).